KR101505884B1 - 만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제 - Google Patents

만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제 Download PDF

Info

Publication number
KR101505884B1
KR101505884B1 KR1020087030717A KR20087030717A KR101505884B1 KR 101505884 B1 KR101505884 B1 KR 101505884B1 KR 1020087030717 A KR1020087030717 A KR 1020087030717A KR 20087030717 A KR20087030717 A KR 20087030717A KR 101505884 B1 KR101505884 B1 KR 101505884B1
Authority
KR
South Korea
Prior art keywords
prostatitis
estrogen
estrogen receptor
prostate
aromatase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087030717A
Other languages
English (en)
Korean (ko)
Other versions
KR20090027640A (ko
Inventor
리스토 산티
토미 스트렝
카이야 할로넨
제니 베르노울리
엠라흐 야트킨
Original Assignee
호르모스 메디칼 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 호르모스 메디칼 리미티드 filed Critical 호르모스 메디칼 리미티드
Publication of KR20090027640A publication Critical patent/KR20090027640A/ko
Application granted granted Critical
Publication of KR101505884B1 publication Critical patent/KR101505884B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020087030717A 2006-05-22 2007-05-22 만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제 Expired - Fee Related KR101505884B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80265706P 2006-05-22 2006-05-22
US60/802,657 2006-05-22
PCT/IB2007/001321 WO2007135547A2 (en) 2006-05-22 2007-05-22 Selective estrogen receptor modulators or aromatase inhibitors for treating chronic nonbacterial prostatitis

Publications (2)

Publication Number Publication Date
KR20090027640A KR20090027640A (ko) 2009-03-17
KR101505884B1 true KR101505884B1 (ko) 2015-03-25

Family

ID=38610674

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087030717A Expired - Fee Related KR101505884B1 (ko) 2006-05-22 2007-05-22 만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제

Country Status (13)

Country Link
US (1) US7825107B2 (https=)
EP (1) EP2029128B1 (https=)
JP (1) JP5123935B2 (https=)
KR (1) KR101505884B1 (https=)
CN (1) CN101448490A (https=)
AU (1) AU2007252991B2 (https=)
BR (1) BRPI0712103A2 (https=)
CA (1) CA2652783C (https=)
ES (1) ES2551690T3 (https=)
MX (1) MX2008014825A (https=)
NO (1) NO341185B1 (https=)
RU (1) RU2480207C2 (https=)
WO (1) WO2007135547A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
USD785586S1 (en) 2014-10-01 2017-05-02 Samsung Electronics Co., Ltd. Portable electronic device
USD779449S1 (en) 2014-10-01 2017-02-21 Samsung Electronics Co., Ltd. Portable electronic device
USD797713S1 (en) 2014-10-01 2017-09-19 Samsung Electronics Co., Ltd. Portable electronic device
USD803818S1 (en) 2014-10-01 2017-11-28 Samsung Electronics Co., Ltd. Portable electronic device
USD795855S1 (en) 2014-10-01 2017-08-29 Samsung Electronics Co., Ltd. Portable electronic device
USD784972S1 (en) 2014-10-01 2017-04-25 Samsung Electronics Co., Ltd. Portable electronic device
USD779450S1 (en) 2014-10-01 2017-02-21 Samsung Electronics Co., Ltd. Portable electronic device
USD781275S1 (en) 2014-10-01 2017-03-14 Samsung Electronics Co., Ltd. Portable electronic device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010006218A (ko) * 1997-04-09 2001-01-26 피터 지. 스트링거 선택적 에스트로겐 수용체 조절제를 이용한 전립선암 및 양성 전립선 비대증의 치료 또는 예방 방법
US6410043B1 (en) * 1998-05-07 2002-06-25 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
KR20060016763A (ko) * 2003-06-05 2006-02-22 호르모스 메디칼 코포레이션 하위 비뇨관 증상들의 치료 또는 예방 방법
KR20060130788A (ko) * 1999-11-08 2006-12-19 유니버시티 오브 테네시 리서치 파운데이션 전립선암의 화학적 예방법

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (https=) * 1962-09-13
US4656187A (en) * 1981-08-03 1987-04-07 Eli Lilly And Company Treatment of mammary cancer
FI77839C (fi) 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
GB2126576B (en) * 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
GB2196003A (en) 1986-09-11 1988-04-20 Nat Res Dev Iodo-and bromo-tamoxifen derivatives
US4869155A (en) * 1988-07-11 1989-09-26 The Grieve Corporation Airflow distribution system for discharging air from a thin plenum, and oven employing same
US4977906A (en) * 1989-03-07 1990-12-18 Scipio William J Di Diurnal rehabilitation for incontinence trainer
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
JPH06504522A (ja) 1990-10-01 1994-05-26 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 高親和性タモキシフェン誘導体とその使用
US6096874A (en) 1990-10-01 2000-08-01 Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives
US5219548A (en) * 1990-10-01 1993-06-15 Board Of Regents, The University Of Texas System High affinity halogenated-tamoxifen derivatives and uses thereof
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5196435A (en) * 1991-11-21 1993-03-23 Eli Lilly And Company Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US5446203A (en) * 1992-08-25 1995-08-29 New York University Synthesis of haloenones and aryl or alkyl substituted enones or alkenes
GB2273704B (en) 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
RU2077889C1 (ru) * 1993-02-24 1997-04-27 Малое государственное предприятие "Флора" Способ лечения хронического простатита
DE4335876A1 (de) * 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
US5650425A (en) 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US5658931A (en) * 1994-09-20 1997-08-19 Eli Lilly And Company Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
CN1167437A (zh) * 1994-11-29 1997-12-10 赫彻斯特马里恩鲁斯公司 用三芳基-乙烯衍生物治疗和预防骨质疏松的方法
US5821254A (en) * 1995-02-17 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
GB9509572D0 (en) 1995-05-11 1995-07-05 Cancer Res Campaign Tech Cancer therapy
DE19526146A1 (de) * 1995-07-07 1997-01-09 Schering Ag Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
WO1997026876A1 (en) 1996-01-29 1997-07-31 Eli Lilly And Company Methods of increasing sphincter competence
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
JP2001502302A (ja) 1996-09-19 2001-02-20 アメリカン・ホーム・プロダクツ・コーポレイション 尿失禁を治療する方法
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
GB9803521D0 (en) 1998-02-19 1998-04-15 Orion Yhtymo Oy New compounds and pharmaceutical compositions thereof
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU4701299A (en) * 1998-06-23 2000-01-10 Stuart R. Adler Therapeutic applications of estrogenic carboxylic acids
AU766648B2 (en) * 1999-03-17 2003-10-23 Axys Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
TW593256B (en) * 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
WO2002003989A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
RU2184543C1 (ru) * 2001-05-24 2002-07-10 Московская медицинская академия им. И.М.Сеченова Способ лечения хронического простатита
JP4301763B2 (ja) * 2001-10-31 2009-07-22 藤倉化成株式会社 銀化合物ペースト
JP2005512995A (ja) 2001-11-09 2005-05-12 ファイザー ヘルス アーベー 不安定又は過活動膀胱を治療するための抗ムスカリン剤及びエストロゲンアゴニスト

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010006218A (ko) * 1997-04-09 2001-01-26 피터 지. 스트링거 선택적 에스트로겐 수용체 조절제를 이용한 전립선암 및 양성 전립선 비대증의 치료 또는 예방 방법
US6410043B1 (en) * 1998-05-07 2002-06-25 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
KR20060130788A (ko) * 1999-11-08 2006-12-19 유니버시티 오브 테네시 리서치 파운데이션 전립선암의 화학적 예방법
KR20060016763A (ko) * 2003-06-05 2006-02-22 호르모스 메디칼 코포레이션 하위 비뇨관 증상들의 치료 또는 예방 방법

Also Published As

Publication number Publication date
ES2551690T3 (es) 2015-11-23
WO2007135547A3 (en) 2008-02-07
EP2029128B1 (en) 2015-08-05
MX2008014825A (es) 2008-12-01
CA2652783C (en) 2015-07-14
AU2007252991B2 (en) 2012-08-02
WO2007135547A2 (en) 2007-11-29
JP5123935B2 (ja) 2013-01-23
CN101448490A (zh) 2009-06-03
US7825107B2 (en) 2010-11-02
RU2008150489A (ru) 2010-06-27
AU2007252991A1 (en) 2007-11-29
US20080021111A1 (en) 2008-01-24
CA2652783A1 (en) 2007-11-29
JP2009537629A (ja) 2009-10-29
RU2480207C2 (ru) 2013-04-27
NO341185B1 (no) 2017-09-04
KR20090027640A (ko) 2009-03-17
NO20084822L (no) 2008-12-15
EP2029128A2 (en) 2009-03-04
BRPI0712103A2 (pt) 2012-01-17

Similar Documents

Publication Publication Date Title
KR101505884B1 (ko) 만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제
Starek-Świechowicz et al. Endogenous estrogens—breast cancer and chemoprevention
US10780063B2 (en) Method for the treatment or prevention of lower urinary tract symptoms
Robertson ICI 182,780 (Fulvestrant™)–the first oestrogen receptor down-regulator–current clinical data
TWI224002B (en) Pharmaceutical compositions for treating prostate hypertrophy and prostate cancer
Clement et al. D2-like receptors mediate the expulsion phase of ejaculation elicited by 8-hydroxy-2-(di-N-propylamino) tetralin in rats
CN101951933A (zh) 治疗良性前列腺肥大、前列腺炎、前列腺病和前列腺癌的组合物
Wardley FULVESTRANT: A REVIEW OF ITS DEVELOPMENT, PRE‐CLINICAL AND CLINICAL DATA
Charalambous et al. Sulindac inhibits colorectal tumour growth, but not prostaglandin synthesis in the rat
Grauso et al. Gynaecology & Obstetrics

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20171228

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20181227

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20191227

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20210312

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20220304

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230320

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230320